FIB-4 is NOT reliable in patients under 35 years old
The FIB-4 index performs poorly in patients under 35 years and should not be used as a screening tool in this age group. The diagnostic accuracy is unacceptably low, with studies showing near-zero sensitivity for detecting advanced fibrosis in young adults.
Evidence for Poor Performance in Young Patients
The most compelling evidence comes from a large European multicenter study that directly assessed FIB-4 performance across age groups 1. In patients ≤35 years old:
- AUROC was only 0.60 for detecting advanced fibrosis (F3-F4)
- This represents poor discriminatory ability, barely better than chance
- The test performed significantly worse than in patients >35 years, where AUROCs ranged from 0.77-0.84
A second study in chronic hepatitis B patients aged <30 years confirmed these findings 2:
- AUROC was 0.57 for significant fibrosis
- AUROC was 0.63 for cirrhosis
- Both values indicate poor diagnostic performance
The most recent 2026 data further validates this concern 3: FIB-4 had 0.0% sensitivity for detecting increased liver stiffness in patients aged 18-35 years, meaning it missed every single case of significant liver disease in this age group.
Why FIB-4 Fails in Young Patients
The fundamental problem is that age is a component of the FIB-4 formula (age × AST / [platelet count × √ALT]). In younger patients, the age numerator artificially suppresses the score, making it nearly impossible to reach thresholds that indicate fibrosis, even when significant disease is present 4.
Guideline Recommendations
Current EASL 2021 guidelines acknowledge that older age affects diagnostic accuracy of FIB-4 5, though they focus more on the elderly population where higher cutoffs are needed. The guidelines note FIB-4 was validated primarily in patients aged 35-65 years, implicitly suggesting caution outside this range.
The 2025 AASLD systematic review 6 provides performance data but does not specifically address the under-35 population, reflecting the lack of validation in this age group.
What to Use Instead
For patients under 35 years with suspected liver disease:
- Proceed directly to imaging-based assessment (transient elastography/FibroScan) rather than relying on FIB-4
- Consider liver biopsy if non-invasive imaging suggests significant fibrosis
- Alternative blood biomarkers like ELF™ or FibroTest® may perform better, though data in young patients remains limited 5
- Clinical judgment based on risk factors (obesity, diabetes, alcohol use) should guide referral decisions
Critical Pitfall to Avoid
Do not use a low FIB-4 score (<1.3) to rule out liver disease in patients under 35 years. The false negative rate is unacceptably high, and you will miss clinically significant fibrosis. A recent study showed FIB-4-based pathways failed to detect approximately 60% of patients with elevated liver stiffness ≥8 kPa 3.